Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S5.60
P/E—
Fwd P/E21.53
PEG1.23
52W— – —
RSI—
Target$229.09 (+14.5%)
Beta0.81
Div0.72%
Loading chart…
RSI ()
Loading patterns…
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 41
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
7Bullish
4Bearish
0Neutral
Momentum Signals 11
▲ MACD Bullish Crossover
▲ Bull Flag
▲ Bull Flag
▲ MACD Bullish Crossover
No major reversal patterns in the last 4 months — showing momentum signals only.
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
88%
7/8 quarters
Wall Street Consensus
STRONG BUY
BuyHoldSell
Price Target Range
$229.09
+14.5% upside
Low $195
—
High $310
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
58.75%Last 12 Months
Operating Margin
19.78%Last 12 Months
Return on Equity
7.61%Last 12 Months
Revenue Growth
5.50%Year over Year
Free Cash Flow
4.33BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
52.97Most Recent Quarter
Current Ratio
1.65Most Recent Quarter
Cash
4.35BMost Recent Quarter
Total Debt
27.86BMost Recent Quarter
Net Debt
—Most Recent Quarter
How DHR Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 140.70B |
| Enterprise Value | 164.22B |
| Trailing P/E | 35.74 |
| Forward P/E | 21.53 |
| PEG Ratio (5yr) | 1.23 |
| Price/Sales (ttm) | 5.60 |
| Price/Book (mrq) | 2.68 |
| EV/Revenue | 6.54 |
| EV/EBITDA | 20.45 |
Share Statistics
| Avg Vol (3m) | 4.63M |
| Shares Outstanding | 702.99M |
| Float | 625.87M |
| % Held by Insiders | 10.96% |
| % Held by Institutions | 84.40% |
| Short Ratio | 2.83 |
| Short % of Float | 1.54% |
Profitability
| Gross Margin | 58.75% |
| Operating Margin (ttm) | 19.78% |
| Profit Margin | 15.95% |
| Return on Assets (ttm) | 3.95% |
| Return on Equity (ttm) | 7.61% |
Income Statement
| Revenue (ttm) | 25.11B |
| Revenue Growth (yoy) | 5.50% |
| Gross Profit (ttm) | 14.75B |
| EBITDA | 8.03B |
| Net Income (ttm) | 3.99B |
| Diluted EPS (ttm) | 5.60 |
| EPS Growth (yoy) | 59.70% |
Balance Sheet
| Total Cash (mrq) | 4.35B |
| Total Debt (mrq) | 27.86B |
| Debt / Equity (mrq) | 52.97 |
| Current Ratio (mrq) | 1.65 |
| Book Value / Share | 74.81 |
| Operating CF (ttm) | 6.63B |
| Free Cash Flow (ttm) | 4.33B |
Trading & Dividends
| Beta (5Y) | 0.81 |
| 50-Day MA | 202.25 |
| 200-Day MA | 202.53 |
| Fwd Dividend Yield | 0.80% |
| Payout Ratio | 25.67% |
Income
Dividend Yield
0.72%Last 12 Months
Annual Rate
1.60Forward
Payout Ratio
25.67%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 25.67%
Monthly Dividends
Ownership Breakdown
Institutional 84.40%
Insider 10.96%
Public 4.6%
Short Interest
1.54% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in DHR in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|